Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):618–249.
   Web of Science ®Google Scholar
• Organization WH. The Global Cancer Observatory. 2021. Accessed 29/9, 2021.
   Google Scholar
• Hay SI, Abajobir AA, Abate KH, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the global burden of disease study 2016. The Lancet. 2017;390(10100):1260–1344.
   PubMed Web of Science ®Google Scholar
• Kim Y-J, Oremus M, Chen HH, et al. Cost-Effectiveness analysis of afatinib, erlotinib, and gefitinib as First-Line treatments for EGFR Mutation-Positive Non-Small-Cell lung cancer in Ontario, Canada. Pharmacoeconomics. 2021;39(5):537–548.
   PubMed Web of Science ®Google Scholar
• Chouaid C, Bensimon L, Clay E, et al. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. Lung Cancer. 2019;127:44–52.
   PubMed Web of Science ®Google Scholar
• ONCOLOGY CSOC. Guidelines of chinese society of clinical oncology (csco) for immune checkpoint inhibitor clinical practice 2021. People 's medical Publishing House; 2021.
   Google Scholar
• Yang Y, Wang Z, Fang J, et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, Double-Blind, phase 3 study (oncology pRogram by InnovENT anti-PD-1-11). J Thorac Onco. 2020;15(10):1636–1646.
   PubMed Web of Science ®Google Scholar
• Innovent Biologics I. U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer. 2021. Accessed 10/27, 2021.
   Google Scholar
• Yang Y, Sun J, Wang Z, et al. Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study. J Thorac Onco. 2021;16(12):2109–2120.10.
   PubMed Web of Science ®Google Scholar
• Liu G, Wu J, Wu J, et al. China guidelines for pharmacoeconomic evaluations 2020. Beijing: China Market Press; 2020.
   Google Scholar
• Woods B, Sideris E, Palmer S, et al. NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review. 2017. Available from: http://www.nicedsu.org.uk
   Google Scholar
• Rui M, Wang Y, Fei Z, et al. Will the markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3):373–380.
   PubMed Web of Science ®Google Scholar
• Zhou C, Chen G, Huang Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021;9(3):305–314.
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades AE, Ouwens MJNM, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9.
   PubMed Web of Science ®Google Scholar
• Longworth L, Rowen D. NICE DSU technical support document 10: the use of mapping methods to estimate health state utility values. 2011. Available from: http://www.nicedsu.org.uk
   Google Scholar
• Khan I, Morris S, Pashayan N, et al. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients. Health Qual Life Outcomes. 2016;14(1):60.
   PubMed Web of Science ®Google Scholar
• Rui M, Li H. Cost-effectiveness of osimertinib vs docetaxel-bevacizumab in third-line treatment in EGFR T790M resistance mutation advanced Non-Small Cell Lung Cancer in China. Clin Ther. 2020;42(11):2159–2170. e2156.
   PubMed Web of Science ®Google Scholar
• Nafees B, Lloyd AJ, Dewilde S, et al. Health state utilities in non-small cell lung cancer: an international study. Asia Pac J Clin Oncol. 2017;13(5):e195–e203.
   PubMed Web of Science ®Google Scholar
• Tolley K, Goad C, Yi Y, et al. Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia. Eur J Health Econ. 2013;14(5):749–759.
   PubMed Web of Science ®Google Scholar
• Wan X, Luo X, Tan C, et al. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: a United States-based cost-effectiveness analysis. Cancer. 2019;125(20):3526–3534.
   PubMed Web of Science ®Google Scholar
• Wehler M-S-S-ke. A health state utility model estimating the impact of ivosidenib on quality of life in patients with relapsed/refractory acute myeloid leukemia. EHA Library. 2018;22(6):567–576.
   Google Scholar
• Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
   Google Scholar
• Delea TE, Zhang X, Amdahl J, et al. Cost effectiveness of blinatumomab versus inotuzumab ozogamicin in adult patients with relapsed or refractory B-Cell precursor acute lymphoblastic leukemia in the United States. Pharmacoeconomics. 2019;37(9):1177–1193.
   PubMed Web of Science ®Google Scholar
• Galve-Calvo E, González-Haba E, Gostkorzewicz J, et al. Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2- advanced or metastatic breast cancer in Spain. Clinicoecon Outcomes Res. 2018;10:773–790.
   PubMed Web of Science ®Google Scholar
• Wang F, Qin S, Sun X, et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. J Hematol Oncol. 2020;13(1):47.
   PubMed Web of Science ®Google Scholar
• Latimer NR, Abrams KR, Lambert PC, et al. Adjusting for treatment switching in randomised controlled trials – A simulation study and a simplified two-stage method. Stat Methods Med Res. 2017;26(2):724–751.
   PubMed Web of Science ®Google Scholar
• Latimer NR, Abrams KR, Siebert U. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring. BMC Med Res Methodol. 2019;19(1):69.
   PubMedGoogle Scholar